Lyell Immunopharma, Inc. (LYEL) Operating income 2019–2025
Lyell Immunopharma, Inc. (LYEL) annual operating income history from SEC filings — each fiscal year as reported.
-$269.4MFY2025 · since FY2019: -$102.1M → -$269.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$269.4M | +24.9% |
| FY2024 | -$358.8M | -45.2% |
| FY2023 | -$247.0M | -32.0% |
| FY2022 | -$187.1M | +12.9% |
| FY2021 | -$214.8M | -1.3% |
| FY2020 | -$211.9M | -107.6% |
| FY2019 | -$102.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice